About Us

Today, precision diagnostics remain expensive, time-consuming, and difficult to scale, which makes early detection inaccessible to many. As a result, countless diseases go unnoticed until it is too late for effective intervention.

Our Vision

At Molsentech, we are redefining the future of precision diagnostics.

By harnessing ultra-precise microfluidic biochips, we dramatically reduce the cost and complexity of diagnostics. This breakthrough enables true early detection and timely treatment, particularly for chronic and progressive diseases such as cancer and dementia. When diagnosed at an early stage, patients can receive simpler and more affordable therapies, avoiding the need for complex late-stage treatments such as immunotherapy, gene therapy, or cell therapy, which may cost over 100 times more.

Our vision goes beyond individual care. By deploying rapid and scalable testing infrastructure at airports, seaports, and other key entry points, we are building a global disease surveillance network. This allows infected individuals to be identified before community transmission occurs. Through targeted isolation and zone-based containment, we can significantly reduce transmission rates (R₀) and provide valuable lead time for vaccine development and coordinated public health response. In doing so, we can help prevent localized outbreaks from escalating into full-scale pandemics.

We believe in the universal value of life, and we are committed to the principle that equitable and effective healthcare should be a global standard, not a luxury.

At Molsentech, we are developing the next generation of precision diagnostics: Sharper. Smarter. Quicker.

Management Team

Dr. M.C. Lin

Chairman

Dr. Sharon Chu

Chief Executive Officer

Gary Wang

Chief Financial Officer

Dr. Leanna Hsieh

Chief Medical Officer

Jenny Liu

R&D Lead

Dr. C.T. Chiu

Biomedical Scientist

S.Y. Yeh

BD Lead (US Region)

Board Members

Image hover effect image

Glenn Gao

Board of Director

Image hover effect image

Peter Chin

Board of Director

Dr. Li Chiang

Board of Director

Image hover effect image

Dr. Wan-ting Huang

Board Supervisor

Awards & Achievements

Milestones

1997

BioFET research team in Academia Sinica

2014

Molsentech was founded

2016

Co-developed BioFET sensors with TSMC

2019

Established laboratory in National Biotechnology Research Park

Selected in Merck Innovation Program

2020

Won the “Innovation and Technology Epidemic Prevention Field Verification Project” from the Ministry of Science and Technology (MOST)

Won the “Industrial Upgrading and Innovation Platform Project” from the Industrial Development Bureau (IDB)

Completed Pre-A round financing and secured NT$40 millions investment.

2021

Obtained the world’s first BioFET EUA for COVID-19 diagnostics from Taiwan Food and Drug Administration (TFDA)

2022

Selected in UC Berkeley SkyDeck Pad13

2024

Won the regional champion of Startup World Cup

Completed A1 round financing and secured NT$107 millions investment.